Can-Fite Announces Exercise of Warrants for Approximately $5.0 Million in Gross Proceeds
RAMAT GAN, Israel, Aug. 08, 2024 (GLOBE NEWSWIRE) — Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company…
Pharmaceuticals, Biotechnology and Life Sciences
RAMAT GAN, Israel, Aug. 08, 2024 (GLOBE NEWSWIRE) — Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company…
TUS+VEN+HMA Triplet Protocol in Frontline Therapy for Newly Diagnosed AML was Reviewed by the FDA and Allowed to Proceed Abstract…
Unveiled new positive survival data for amezalpat (TPST-1120) in randomized first-line hepatocellular carcinoma (“HCC”) study demonstrating: Survival benefit maintained across…
GRANTS, NEW MEXICO, Aug. 08, 2024 (GLOBE NEWSWIRE) — Bright Green Corporation (Nasdaq: BGXX) (“Bright Green” or the “Company”) today…
SAN DIEGO, Aug. 08, 2024 (GLOBE NEWSWIRE) — Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today…
Vincerx continues to enroll its Phase 1 studies of antibody-drug conjugate (ADC) VIP943, with data expected by the end of…
Clinical study reports for the FURI, CARES and NATURE trials in refractory or resistant invasive fungal infections were delivered to…
New Leadership Appointments; Positive Clinical and Regulatory Reports for the Lead Product Candidate, HB-200 (eseba-vec); On track to initiate the…
– NDA for CARDAMYST™ in PSVT accepted by FDA in 2Q 2024; PDUFA in March 2025 – Cash of $83.3 million as…
PRINCETON, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) — ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the…